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SMOKING-CESSATION ACROSS BORDERS:TRANSFERABILITY
OF COST-EFFECTIVENESS RESULTS
Vemer P, Rutten-van Mölken MP
Erasmus MC, Rotterdam,The Netherlands
OBJECTIVES: To identify the factors which drive the CE of
pharmacological smoking cessation therapies (SCTs) between
Netherlands, Germany, Sweden, United Kingdom, Belgium and
France. METHODS: The BENESCO model was used to estimate
the life-time beneﬁts of smoking cessation. The model follows a
cohort of smokers making a single quit attempt using nicotine
replacement therapy (NRT), bupropion, varenicline or no phar-
macology. The factors investigated were age- and gender-speciﬁc
smoking prevalence, demography, overall mortality, epidemiol-
ogy and costs of smoking-related diseases, utilities, resource use
and unit costs of SCTs, discount rates and percentage of smokers
making a quit attempt. The Netherlands was used as reference.
We systematically replaced Dutch model parameters by country-
speciﬁc values. The inﬂuence of the factors was expressed as the
change in incremental net monetary beneﬁt (INMB), using a
willingness-to-pay (WTP) of 20,000 Euro per QALY. Factors
were ranked on their impact. RESULTS: The INMB of NRT
versus unaided cessation varies from 0.38 million per 1000 quit
attempts in Germany to 1.54 million in Belgium. The INMB was
inﬂuenced most by smoking prevalence, discount rates, epidemi-
ology and then utilities. The change in INMB of NRT versus
unaided cessation due to smoking prevalence varied from -57%
to +8%. The change due to discount rates ranged from -65% to
+62% compared to the Netherlands. The rank order of the
factors depended on the threshold value. At a WTP of 1,000
Euro, the ranking was resource use, smoking prevalence, costs of
illnesses and then discount rates. Rankings were largely similar
for the other comparisons. CONCLUSIONS: Although each
pharmacotherapy had very positive INMBs there were signiﬁcant
differences across countries, which were primarily related to
choice of discount rate and smoking prevalence. Methodological
choices can have a big inﬂuence on CE results.
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THIRD-GENERATION AROMATASE INHIBITORSVS
TAMOXIFEN INTHETREATMENT OF EARLY AND ADVANCED
BREAST CANCER: A SYSTEMATIC REVIEW OF RANDOMISED
CONTROLLEDTRIALS
von Maltzahn R, Edwards SJ
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: To compare the efﬁcacy of third-generation aro-
matase inhibitors (AIs) with tamoxifen in the treatment of early
and advanced breast cancer (EBC and ABC) in randomised con-
trolled trials (RCTs). METHODS: Systematic review of
CENTRAL, EMBASE, MEDLINE, for RCTs comparing tamox-
ifen with anastrozole, exemestane, or letrozole. Searching was
restricted to English-language publications and was completed in
March 2008. Mortality and relapse data were extracted for EBC
studies at 2 and 5 years post randomisation. For ABC, primary
outcomes were disease progression and response. Meta-analysis
was conducted with a ﬁxed effects model using the Mantel-
Haenszel method. Summary effect estimates (Relative Risk [RR])
with 95% conﬁdence intervals (95%CI) were calculated (nega-
tive outcomes, e.g. mortality, favour AIs when RR < 1.0; positive
outcomes, e.g. clinical beneﬁt, favour AIs when RR > 1.0).
RESULTS: The literature search identiﬁed 2417 papers, 15 pro-
vided data on 9 RCTs comparing third-generation AIs with
tamoxifen. The results for EBC presented a range of ﬁndings in
favour of AIs at 2 and 5 years with statistically signiﬁcant out-
comes at 2 years: all cause mortality (RR 0.86, 95%CI: 0.77,
0.97); contralateral recurrence (RR 0.53, 95%CI: 0.38, 0.74);
distant recurrence (RR 0.75, 95%CI: 0.67, 0.84); local recur-
rence (RR 0.80, 95%CI: 0.66, 0.96); and 5 years: contralateral
recurrence (RR 0.57, 95%CI: 0.42, 0.76); distant recurrence (RR
0.86, 95%CI: 0.78, 0.94); local recurrence (RR 0.64; 95%CI:
0.48, 0.87). For ABC there were signiﬁcant differences between
AIs and tamoxifen for: clinical beneﬁt (RR1.19, 95%CI:1.09,
1.3); complete response (RR 1.82, 95%CI:1.22, 2.73); objective
response (RR 1.58, 95%CI: 1.28, 1.97); partial response (RR1.2,
95%CI 1.02, 1.41) and disease progression (RR0.83,
95%CI:0.76, 0.92). Adjusted indirect comparison of individual
AIs were conducted with no signiﬁcant differences identiﬁed.
CONCLUSIONS: Treatment with third-generation AIs rather
than tamoxifen provides signiﬁcantly better outcomes for ABC
and for EBC at two and ﬁve years follow up.
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EFFICACY OF LEUPRORELIN 3.75MG COMPAREDTO 7.5MG IN
THETREATMENT OF PROSTATE CANCER: SYSTEMATIC
REVIEW AND META-ANALYSIS
Payne HA1, Edwards SJ2
1University College London Hospitals, London, UK, 2AstraZeneca UK
Ltd, Luton, UK
OBJECTIVES: To compare the leuprorelin UK licensed dose
(3.75 mg) with the USA licensed dose (7.5 mg) in the treatment
of prostate cancer. METHODS: Systematic review of
CENTRAL, BIOSIS, EMBASE and MEDLINE for clinical trials
in patients with prostate cancer treated with leuprorelin was
conducted in March 2008. Data on overall response (a composite
of complete response, partial response and stable disease) were
extracted. Summary effect estimate (Relative Beneﬁt, RB) was
calculated by meta-analysis using Bayesian Markov Chain
Monte Carlo simulation. The probability of a treatment having
the greatest overall response was calculated as the proportion of
simulations in which that treatment had the greatest relative
efﬁcacy. RESULTS: Of the 1242 papers initially identiﬁed in the
literature search, only 4 were found to be head-to-head compari-
sons of leuprorelin 3.75 mg vs 7.5 mg. Two of the 4 papers were
reports of the same study, providing 3 studies for inclusion in the
meta-analysis. The relative beneﬁt of leuprorelin 7.5 mg over
3.75 mg was found to be 11% (RB 1.11; 95% Credible Interval:
0.60 to 1.86), which equates to a mean absolute beneﬁt of 9.1%.
The probability of the higher dose being more effective than the
lower dose was 68.1%. A sample size of 585 would be required
for a clinical study designed to conﬁrm the estimated 9.1%
beneﬁt of leuprorelin 7.5 mg over 3.75 mg (90% power, 5%
signiﬁcance level). A similar study of 5590 patients would be
required to conﬁrm the clinical equivalence of the two doses
(assuming minimum clinically important overall response 3%),
providing the study failed to demonstrate a 3% difference.
CONCLUSIONS: A Bayesian meta-analysis of the available
evidence suggests that leuprorelin 7.5 mg may be more effective
in terms of overall response than the 3.75 mg dose. Further
research is required to conﬁrm the superiority of the higher dose
or clinical equivalence between the two doses.
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